NCT00033267View on ClinicalTrials.gov

CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma

PHASE2CompletedINTERVENTIONAL
Enrollment

27

Participants

Timeline

Start Date

April 30, 2002

Primary Completion Date

February 28, 2006

Study Completion Date

February 29, 2008

Conditions
Recurrent Mantle Cell Lymphoma
Interventions
DRUG

temsirolimus

Given IV

Trial Locations (1)

55905

North Central Cancer Treatment Group, Rochester

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00033267 - CCI-779 in Treating Patients With Mantle Cell Non-Hodgkin's Lymphoma | Biotech Hunter | Biotech Hunter